Drug Development

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Articles

PharmTech interviewed Sartorius about SUS innovations and trends.

 Single-Use Systems in Downstream Processes

The acquisition will include Rewrite’s DNA writing platform, expanding Intellia’s genome editing tools.

Intellia Therapeutics Acquires Rewrite Therapeutics

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Analytical approaches must keep pace to ensure the identity, safety, and efficacy of evolving mRNA candidates.

Analysis of mRNA Therapeutics and Vaccines

Yeli Zhang is North America Technical Manager IFF Pharma Solutions, Wilmington, DE.

Elizabeth Tocce is associate application development engineer, Dupont.

Holly Bertrand is Research Investigator IFF Pharma Solutions, Wilmington, DE.

Kevin McIntyre is Laboratory Supervisor, IFF Pharma Solutions, Wilmington, DE.

Fernanda Onofre, Americas Regional Applications Leader, IFF Pharma Solutions, Wilmington, DE.

Amina Faham is Global Director of Applications Development & Innovation; IFF Pharma Solutions, Wilmington, DE.

In this study, researchers evaluated the colloidal microcrystalline cellulose (cMCC) suspending agent—a co-processed material of microcrystalline cellulose and sodium carboxymethyl cellulose (NaCMC)—by using a representative pharmaceutical-grade commercial version of cMCC.

Polymer Influence on the Rheological Properties of Co-Processed Microcrystalline Cellulose and Sodium Carboxymethylcellulose

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The global nature of the COVID-19 pandemic emphasizes the critical importance of expanded vaccination.

Global Vaccine Access Challenges FDA and Industry

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Toxicology studies are an important and required aspect of drug development that are performed to ensure that drugs are deemed safe prior to patient administration and use in clinical trials.

Predicting Toxicity in Drug Development

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

Cytiva Provides Arranta Bio with Single-Use Manufacturing Platform for mRNA Products

A key benefit for companies when outsourcing formulation development is the broad experience they can gain from a dedicated service provider, particularly for niche markets.

Gaining Formulation Expertise through Partnerships

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal 

Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.



Formulation and Drug Delivery